Back to Search
Start Over
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
- Source :
- Case Reports in Oncology, Case Reports in Oncology, Vol 13, Iss 3, Pp 1483-1489 (2020)
- Publication Year :
- 2020
- Publisher :
- S. Karger AG, 2020.
-
Abstract
- The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1 negative, experienced a prompt and exceptionally favorable response to pembrolizumab monotherapy. After cessation of treatment due to immune-related endocrinopathies, complete metabolic response on interim PET/CT scan was achieved. Two years after initial diagnosis, unifocal tumor reactivation was addressed with successful pembrolizumab monotherapy rechallenge. Immunotherapy, typically not used as frontline treatment for malignant pleural mesothelioma, may provide an effective and durable response for some patients. Based on this single case study, epithelioid type tumors with strongly positive PD-L1 and BAP1-negative immunohistochemical markers may be well suited for treatment with immune checkpoint inhibitors such as pembrolizumab.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
medicine.medical_treatment
Immune checkpoint inhibitors
Case Report
Immune checkpoint inhibitor
Pembrolizumab
lcsh:RC254-282
Programmed cell death ligand 1
03 medical and health sciences
0302 clinical medicine
Internal medicine
Malignant pleural mesothelioma regression
Medicine
Immune-related endocrinopathy
BAP1
business.industry
Pleural mesothelioma
Pembrolizumab monotherapy
Immunotherapy
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Interim pet
Programmed cell death ligand 1 expression
Therapeutic biomarkers
030104 developmental biology
030220 oncology & carcinogenesis
Immunohistochemistry
business
Subjects
Details
- ISSN :
- 16626575
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Case Reports in Oncology
- Accession number :
- edsair.doi.dedup.....777b19b781bd2f3ec9450b7be6978170